Author name cluster

Jan Booij

Possible papers associated with this exact author name in Arrow. This page groups case-insensitive exact name matches and is not a full identity disambiguation profile.

7 papers

1 author row

YNICL Journal 2020 Journal Article

The muscarinic M1 receptor modulates associative learning and memory in psychotic disorders

Geor Bakker
Claudia Vingerhoets
Oswald J.N. Bloemen
Barbara J. Sahakian
Jan Booij
Matthan W.A. Caan
Thérèse A.M.J. van Amelsvoort

BACKGROUND: receptor signaling in psychotic disorders. METHODS: I-IDEX single photon emission computed tomography. RESULTS: receptor binding in the DLPFC was related to greater functional sensitivity to biperiden of the cingulate gyrus during the memory phase. CONCLUSION: receptor reserve in temporal-limbic areas.

Details DOI

YNICL Journal 2019 Journal Article

Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study

Merijn Joling
Chris Vriend
Pieter G.H.M. Raijmakers
Jessica J. van der Zande
Afina W. Lemstra
Henk W. Berendse
Jan Booij
Odile A. van den Heuvel

Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are thought to be part of a spectrum: both have a clinical profile including symptoms associated with dopaminergic and serotonergic loss, yet few imaging studies have focused on serotonergic neurodegeneration in both disorders. We aimed to study degeneration of terminals with dopamine and serotonin transporter (DAT and SERT, respectively) in patients with early-stage PD and DLB relative to healthy controls, using 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT) single photon emission computed tomography (SPECT). We conducted region of interest (ROI) and voxel-based analyses on 123I-FP-CIT SPECT scans. Using the cerebellum as a reference region, we determined binding ratios (BRs) for bilateral ROIs in the DAT-rich striatum (head of the caudate nucleus and posterior putamen) and SERT-rich extrastriatal brain regions (thalamus, hypothalamus and hippocampus). We compared BRs in PD and DLB patients with BRs in healthy controls (all groups: n = 16). Both PD and DLB patients had lower striatal 123I-FP-CIT BRs than healthy controls for the bilateral caudate head (PD—left: F(1, 29) = 28. 778, P <. 001, ω 2 = 0. 35; right: F(1, 29) = 35. 338, P <. 001, ω 2 = 0. 42; DLB—left: F(1, 29) = 28. 241, P <. 001, ω 2 = 0. 31; right: F(1, 29) = 18. 811, P <. 001, ω 2 = 0. 26) and bilateral posterior putamen (PD—left: F(1, 29) = 107. 531, P <. 001, ω 2 = 0. 77; right: F(1, 29) = 87. 525, P <. 001, ω 2 = 0. 72; DLB—left: F(1, 29) = 39. 910, P <. 001, ω 2 = 0. 48; right: F(1, 29) = 26. 882, P <. 001, ω 2 = 0. 38). DLB patients had lower hypothalamic 123I-FP-CIT BRs than healthy controls (F(1, 29) = 6. 059, P =. 020, ω 2 = 0. 12). In the voxel-based analysis, PD and DLB patients had significantly lower striatal binding than healthy controls. Both PD patients in the early disease stages and DLB patients have reduced availability of striatal DAT, and DLB patients lower hypothalamic SERT compared with healthy controls. These observations add to the growing body of evidence that PD and DLB are not merely dopaminergic diseases, thereby providing additional clinicopathological insights.

Details DOI

YNICL Journal 2018 Journal Article

Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies

Merijn Joling
Chris Vriend
Jessica J. van der Zande
Afina W. Lemstra
Odile A. van den Heuvel
Jan Booij
Henk W. Berendse

In this retrospective cross-sectional study we compared 123I‑N‑ω‑fluoropropyl‑2β‑carbomethoxy‑3β‑(4‑iodophenyl)nortropane (123I-FP-CIT) binding to the striatal dopamine and the extrastriatal serotonin transporter (DAT and SERT, respectively) between Parkinson's disease (PD) and dementia with Lewy bodies (DLB) to gain more insight in the pathophysiology of the two diseases. We compared 123I-FP-CIT single photon emission computed tomography scans of, age-, gender matched patients with cognitive decline in same range of severity with PD (n = 53) or DLB (n = 53) using a regions of interest (ROIs) approach. We derived ROIs anatomically from individual magnetic resonance imaging brain scans. To corroborate the ROI findings, we performed additional whole-brain voxel-based analyses. In both ROI and voxel-based analyses, 123I-FP-CIT binding in PD patients was significantly lower in the bilateral posterior putamen than in DLB patients (left: F(1, 103) = 18. 363, P < 0. 001, ω 2 = 0. 14; right: F(1, 103) = 20. 434, P < 0. 001, ω 2 = 0. 15) (P corr < 0. 033). Caudate/putamen ratios were also significantly lower in DLB than in PD (U(105) = 724. 0, P < 0. 001). Extrastriatal SERT binding showed no difference between PD and DLB. These results suggest similar involvement of serotonergic structures in the degenerative process in PD and DLB.

Details DOI

YNICL Journal 2018 Journal Article

Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis

Geor Bakker
Claudia Vingerhoets
Daphne Boucherie
Matthan Caan
Oswald Bloemen
Jos Eersels
Jan Booij
Thérèse van Amelsvoort

Background: receptor binding in the DLPFC and hippocampus in relation to cognitive functioning. Methods: I-IDEX, single photon emission computed tomography (SPECT) in 30 medication-free subjects diagnosed with a psychotic disorder. A computerized neuropsychological test battery was used to assess cognition, and the positive and negative syndrome scale (PANSS) to assess severity of psychotic symptoms. Results: in the hippocampus was related to worse delayed recognition of verbal memory. Conclusion: receptor may be an important biomarker in biological stratification of patients with psychotic disorders.

Details DOI

YNICL Journal 2014 Journal Article

Neuroimaging essentials in essential tremor: A systematic review

Sarvi Sharifi
Aart J. Nederveen
Jan Booij
Anne-Fleur van Rootselaar

BACKGROUND: Essential tremor is regarded to be a disease of the central nervous system. Neuroimaging is a rapidly growing field with potential benefits to both diagnostics and research. The exact role of imaging techniques with respect to essential tremor in research and clinical practice is not clear. A systematic review of the different imaging techniques in essential tremor is lacking in the literature. METHODS: We performed a systematic literature search combining the terms essential tremor and familial tremor with the following keywords: imaging, mri, vbm, dwi, fmri, pet and spect, both in abbreviated form as well as in full form. We summarize and discuss the quality and the external validity of each study and place the results in the context of existing knowledge regarding the pathophysiology of essential tremor. RESULTS: A total of 48 neuroimaging studies met our search criteria, roughly divided into 19 structural and 29 functional and metabolic studies. The quality of the studies varied, especially concerning inclusion criteria. Functional imaging studies indicated cerebellar hyperactivity during rest and during tremor. The studies also pointed to the involvement of the thalamus, the inferior olive and the red nucleus. Structural studies showed less consistent results. DISCUSSION AND CONCLUSION: Neuroimaging techniques in essential tremor give insight into the pathophysiology of essential tremor indicating the involvement of the cerebellum as the most consistent finding. GABAergic dysfunction might be a major premise in the pathophysiological hypotheses. Inconsistencies between studies can be partly explained by the inclusion of heterogeneous patient groups. Improvement of scientific research requires more stringent inclusion criteria and application of advanced analysis techniques. Also, the use of multimodal neuroimaging techniques is a promising development in movement disorders research. Currently, the role of imaging techniques in essential tremor in daily clinical practice is limited.

Details DOI

YNIMG Journal 2013 Journal Article

No association between striatal dopamine transporter binding and body mass index: A multi-center European study in healthy volunteers

Elsmarieke van de Giessen
Swen Hesse
Matthan W.A. Caan
Franziska Zientek
John C. Dickson
Livia Tossici-Bolt
Terez Sera
Susanne Asenbaum

Introduction Dopamine is one among several neurotransmitters that regulate food intake and overeating. Thus, it has been linked to the pathophysiology of obesity and high body mass index (BMI). Striatal dopamine D2 receptor availability is lower in obesity and there are indications that striatal dopamine transporter (DAT) availability is also decreased. In this study, we tested whether BMI and striatal DAT availability are associated. Methods The study included 123 healthy individuals from a large European multi-center database. They had a BMI range of 18. 2–41. 1kg/m2 and were scanned using [123I]FP-CIT SPECT imaging. Scans were analyzed with both region-of-interest and voxel-based analysis to determine the binding potential for DAT availability in the caudate nucleus and putamen. A direct relation between BMI and DAT availability was assessed and groups with high and low BMI were compared for DAT availability. Results No association between BMI and striatal DAT availability was found. Conclusion The lack of an association between BMI and striatal DAT availability suggests that the regulation of striatal synaptic dopamine levels by DAT plays no or a limited role in the pathophysiology of overweight and obesity.

Details DOI

YNIMG Journal 2005 Journal Article

Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease

Gerda Andringa
Benjamin Drukarch
John G.J.M. Bol
Kora de Bruin
Karolina Sorman
Jan B.A. Habraken
Jan Booij

The in vivo analysis of dopaminergic degeneration in animal models of Parkinson's disease (PD), using pinhole single photon emission computed tomography (SPECT), ideally should afford a serial study design, enabling the analysis of the degenerative process as well as the potential neuroprotective and/or restorative properties of drugs over time in living animals. Previously, we demonstrated that striatal dopamine transporter (DAT) levels in rats could be analyzed reproducibly, using pinhole SPECT with the DAT probe [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-{4-iodophenyl}nortropane (FP-CIT). However, the capacity of this approach to accurately detect a range of striatal DAT levels in the most widely used animal model of PD, i. e. , the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated mouse, remains to be determined. For this purpose, various levels of DAT were induced by treating c57BL/6J mice for 1, 3, or 5 days with MPTP (25 mg/kg ip), respectively. [123I]FP-CIT SPECT scans were performed 5 days after the last MPTP injection. Mice were perfused 6 days after the last MPTP injection, and the SPECT data were compared to ex vivo striatal and nigral DAT levels as measured by immunohistochemistry within the same animals. The analysis of striatal DAT levels using SPECT and DAT immunohistochemistry yielded highly comparable results on the percentage of DAT reduction in each MPTP group. The in vivo data showed a decrease of specific striatal to non-specific binding ratios by 59%, 82%, and 76% in mice treated for 1, 3, and 5 days, respectively. Moreover, a strong, positive correlation was observed between the in vivo and ex vivo parameters. The present study provides the first evidence that [123I]FP-CIT pinhole SPECT allows the accurate detection of a range of striatal DAT (i. e. , losses of approximately 60–80%) levels in mice. Since such large dopaminergic lesions could be detected, this SPECT method may at least be useful for analyzing neuroprotective treatment with a clear-cut positive (i. e. , complete protection) or negative (i. e. , not any protection) effect. Whether this method is also useful for analyzing more subtle effects of neuroprotective treatment (partial protection) remains to be established, by studying mice with small dopaminergic lesions.

Details DOI